Business UpdateJun 25, 2026, 08:16 AM
BioRestorative completes BRTX-100 Phase 2 clinical trial manufacturing
AI Summary
BioRestorative Therapies announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, a key milestone for its lead cell therapy candidate. This manufacturing was completed in the company's cGMP ISO-7 certified facility, supporting ongoing clinical development for chronic lumbar disc disease. The company emphasized the strategic advantages of its vertically integrated regenerative medicine platform, which enables control over quality, consistency, and scalability for both therapeutic and commercial programs.
Key Highlights
- Successfully completed manufacturing for BRTX-100 Phase 2 clinical trial.
- Manufacturing conducted in the Company's cGMP ISO-7 certified facility.
- BRTX-100 targets chronic lumbar disc disease treatment.
- Company highlights strategic advantage of integrated manufacturing and biologics platform.
- Platform supports both therapeutic candidates (BRTX-100) and commercial BioCosmeceuticals.
- Approach provides consistent, high-quality biologic production and scalable infrastructure.
- Contributes to reduced manufacturing-related expense and improved operating costs.
Price Impact
More from BRTX